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This is the second iteration of the European Society of
Cardiology (ESC) and European Association for the Study of
Diabetes (EASD) joining forces to write guidelines on the
management of the combination of diabetes mellitus (DM),
pre-diabetes, and cardiovascular disease (CVD), designed to
assist clinicians and other healthcare workers to make
evidence based management decisions [1].2. Introduction
The increasing prevalence of DM worldwide has led to a
situation where approximately 360 million people had DM in
2011 (60 million in Europe), of whom more than 95% would
have had type 2 DM (T2DM); another 300 million individuals
had features indicating future risk of developing T2DM,
including fasting hyperglycaemia, impaired glucose tolerance
(IGT), gestational DM and euglycaemic insulin resistance (IR).
Fig. 1 – Investigational algorithm outlining the principles for the diagnosis and management of cardiovascular disease (CVD)
in diabetes mellitus (DM) patients with a primary diagnosis of DM or a primary diagnosis of CVD. The recommended
investigations should be considered according to individual needs and clinical judgement and are not meant as a general
recommendation to be undertaken by all patients. ACS = acute coronary syndrome; ECG = electrocardiogram; FPG = fasting
plasma glucose; HbA1c = glycated haemoglobin A1c; IGT = impaired glucose tolerance; MI = myocardial infarction;
OGTT = oral glucose tolerance test.
Table 1 – Comparison of 2006 World Health Organization
(WHO) and 2003/2011 and 2012 American Diabetes
Association (ADA) diagnostic criteria.
Diagnose/
measurement
WHO
2006/2011
ADA 2003
and 2012
Diabetes
HbA1c Can be used Recommended
If measured
 48 mmol/mol
48 mmol/mol
Recommended
7.0 mmol/L
(126 mg/dL)
FPG or 7.0 mmol/L
(126 mg/dL)
11.1 mmol/L
(200 mg/dL)
or
2hPG 11.1 mmol/L
(200 mg/dL)
IGT <7.0 mmol/L
(<126 mg/dL)
FPG <7.0 mmol/L
(<126 mg/dL)
2hPG 7.8.–<11.1 mmol/L
(140–<200 mg/dL)
Not required
If measured
7.8–11.0 mmol/L
(140–198 mg/dL)
IFG
FPG 6.1–6.9 mmol/L
(110–125 mg/dL)
5.6–6.9 mmol/L
(100–125 mg/dL)
If measured
2hPG <7.8 mmol/L
(<140 mg/dL)
FPG = fasting plasma glucose; IGT = impaired glucose tolerance;
IFG = impaired fasting glucose; 2hPG = 2-h post-load plasma glu-
cose.
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people with DM are related to CVD, which caused physicians in
the ﬁelds of DM and cardiovascular medicine to join forces to
research and manage these conditions (Fig. 1).
3. Abnormalities of glucose metabolism and
cardiovascular disease
3.1. Deﬁnition, classiﬁcation and diagnosis
Deﬁnition, classiﬁcation and diagnosis of impaired glucose
metabolism are presented in Tables 1 and 2. To standardize
glucose determinations, venous plasma measures have been
recommended.
3.2. Epidemiology
The International Diabetes Federation's global burden of DM in
2011 and predictions for 2030 are summarized in Table 3.
3.3. Screening for disorders of glucose metabolism
Population testing of blood glucose to determine CV risk is not
recommended. Screening of hyperglycaemia for CV risk
purposes should therefore be targeted to high-risk individuals.
Several DM risk scores for DM have been developed; the FINnish
Diabetes RIsk SCore is the most commonly used in Europe
(Fig. 2). It is recommended in the general population and
people with assumed abnormalities (obesity, hypertension,
family history of DM). In CVD patients, no diabetes risk score is
needed but an OGTT is indicated if HbA1c and/or fasting
plasma glucose (FPG) are inconclusive.
Fig. 2 – FINnish Diabetes RIsk SCore (FINDRISC) to assess the
10-year risk of type 2 diabetes in adults.
Table 3 – Burden of DM in Europe in 2011 and predictions
for 2030.
Variable 2011 2030
Total population (millions) 896 927
Adults (20–79 years; millions) 651 670
DM (20–79 years)
European prevalence (%) 8.1 9.5
Number with DM (millions) 52.6 64.0
IGT (20–79 years)
Regional prevalence (%) 9.6 10.6
Number with IGT (millions) 62.8 71.3
Type I DM in children (0–14 years)
Number with type I DM (thousands) 115.7 –
Number newly diagnosed/year (thousands) 17.8 –
DM mortality (20–79 years)
Number of deaths; men (thousands) 281.3 –
Number of deaths; women (thousands) 316.5 –
Healthcare expenditure due to DM (20–79 years, Europe)
Total expenditure (billions of s) 75.1 90.2
DM = diabetes mellitus; IGT = impaired glucose tolerance.
Table 2 – Cut-points for diagnosing DM, impaired glucose
tolerance, and impaired fasting glucose based on other
blood specimens than the recommended standard, ve-
nous plasma.
Diagnosis Venous
plasma*
mmol/L
(mg/dL)
Venous
blood
mmol/L
(mg/dL)
Capillary
blood
mmol/L
(mg/dL)
IFG-FG 6.1 (110) 5.0 (90) 5.6 (101)
IGT-2hG 7.8 (140) 6.5 (117) 7.2 (130)
Diabetes-FG 7.0 (126) 5.8 (104) 6.5 (117)
Diabetes-2hG 11.1 (200) 9.4 (169) 10.3 (185)
FPG = fasting plasma glucose; FG = fasting glucose; IFG = impaired
fasting glucose; IGT = impaired glucose tolerance; 2hG = 2-h post-
load glucose; 2hPG = 2-h post-load plasma glucose.
* Standard.
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disease
Several studies have shown that increasing HbA1c is associ-
ated with increasing CVD risk. Comparing all three glycaemic
parameters: FPG, 2hPG and HbA1c simultaneously for mortali-
ty and CVD risk revealed that the association is strongest for
2hPG. Women with newly diagnosed T2DM have a higher
relative risk for CVD mortality than their male counterparts.
The overall relative risk (the ratio of risk in women to risk in
men) was 1.46 (1.21–1.95) in people with DM and 2.29 (2.05–
2.55) in those without, suggesting that the well-known gender
differential in CAD is reduced in DM.
3.5. Delaying conversion to type 2 diabetes mellitus
Modest weight loss and increased physical activity prevent or
delay progression in high-risk individuals with IGT. Thus, those
at high risk for T2DM and those with established IGT should be
given appropriate lifestyle counselling (Tables 4 and 5).4. Molecular basis of cardiovascular disease in
diabetes mellitus
4.1. The cardiovascular continuum in diabetes mellitus
See Fig. 3.
4.2. Pathophysiology of insulin resistance in type 2
diabetes mellitus
Insulin resistance has an important role in the pathophysiology
of T2DM and CVD and both genetic and environmental factors
facilitate its development. More than 90% of people with T2DM
are obese, and the release of free fatty acids (FFAs) and cytokines
from adipose tissue directly impairs insulin sensitivity.
4.3. Endothelial dysfunction, oxidative stress and vascular
inﬂammation
See Fig. 4.
4.4. Macrophage dysfunction
It seems that macrophage abnormalities provide a cellular
link between DM and CVD by both enhancing IR and by
Table 4 – Prevention of T2DM by lifestyle intervention –
the evidence.
Stud y Intervenon Paents (n) Foll ow-up
(years)
RRR
(%)
Da-Qing Study
China
Diet
Exercise
Die t+ exercise
Control
130
141
126
133
6 31
46
42
Dia betes 
Prevenon Stud y
Finla nd
Diet + physical  acvity
Control
265
257
3.2 58
US Dia betes 
Prevenon 
Program
Outcomes Study
USA
diet + physical  acvity
meormin
placebo
1079
1073
1082
2.8 58
31
India n Diabetes 
Prevenon 
Program
India
Lifes tyle
Meorm in
Lifes tyle + meormin
control
133
133
129
136
2.5 29
26
28
Japanese trial in 
men with IGT
Japan
Diet + ex ercise
control
102 356 4 67
Study on li fes tyle-
intervenon and 
IGT
Maastricht study
The Nether lands
Diet + physical  ac vity
control
74
73
3 58
European 
Dia betes 
Prevenon Stud y
New cas tle, UK
Diet + physical  ac vity
control
51
51
3.1 55
Zen sharen Stud y
Japan
Die t + ph ysical  ac vity
control
330
311
3 44
IGT = impaired glucose tolerance; RRR = relative risk reduction;
SLIM = study on lifestyle-intervention and IGT Maastricht.
Absolute risk reduction numbers would have added value but
could not be reported since such information is lacking in several
of the studies.
The Zensharen study recruited people with IFG, while other
studies recruited people with IGT.
Table 6 – Characteristics of dyslipidaemia in type 2
diabetes mellitus.
Dyslipidaemia is a major risk factor for CVD
Dyslipidaemia represents a cluster of lipid and lipoprotein
abnormalities including elevation of both fasting and
post-prandial TG
Apo B, small dense LDL particles, low HDL-C and Apo A
Increased waist circumference and elevation of TG sis a simple
tool to capture high-risk subjects with metabolic syndrome
Apo = apolipoprotein; CVD = cardiovascular disease; HDL-C = high-
density lipoprotein cholesterol; LDL = low-density lipoprotein;
TG = triglyceride; TRL = triglyceride-rich lipoprotein.
Table 5 – Recommendations for diagnosis of disorders of
glucose metabolism.
Diagnosis of disorders of glucose m etab olism
Recommend aons Class         
a
Level    
b
Ref.  c
It is  recommend ed that the diag nosis of diabetes  is  base d on 
HbA1c and FPG combined or on an OGTT if sll in doubt.
I B 2-5,8,10
It is  recommend ed that an OGTT  is  used for diag nosi ng IGT. I B 2-5, 8,10
It is  recommend ed that screening for potenal T2DM in people 
with CV D is  iniated with HbA1c and FPG and that OGTT is 
added if HbA1c and FPG are  inconclusive
I A 36-41
Special  aenon should be consi dered to the appli caon  of 
preve nve  measures  in wome n with disorder s of gl ucose 
metabolism
IIa C -
It is  recommend ed that peop le at high  ris k for T2DM receive 
appropri ate lifes tyle  counselli ng to reduce their  risk of 
developing DM.
I A 59,60
CVD = cardiovascular disease; DM = diabetes mellitus; FPG = fast-
ing plasma glucose; HbA1c = glycated haemoglobin A1c; IGT = im-
paired glucose tolerance; OGTT = oral glucose tolerance test;
T2DM = type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 9 0 – e 2 0 5e194contributing to the development of fatty streaks and vascular
damage.
4.5. Atherogenic dyslipidaemia
See Table 6. It is an independent predictor of CV risk, stronger
than isolated high triglycerides or a low HDL cholesterol.Fig. 3 – Glycaemic continuum a4.6. Coagulation and platelet function
IR and hyperglycaemia participate in the pathogenesis
of a prothrombotic state: increased plasminogen activatornd cardiovascular disease.
Fig. 4 – Hyperglycaemia, insulin resistance, and
cardiovascular disease. AGE = advanced glycated end-
products; FFA = free fatty acids; GLUT-4 = glucose
transporter 4; HDL-C = high-density lipoprotein cholesterol;
LDL = low-density lipoprotein particles; NO = nitric oxide;
PAI-1 = plasminogen activator inhibitor-1; PKC = protein
kinase C; PPARy = peroxisome proliferator-activated
receptor y; PI3K = phosphatidylinositide 3-kinase;
RAGE = AGE receptor; ROS = reactive oxygen species; SR-
B = scavenger receptor B; tPA = tissue plasminogen
activator.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 9 0 – e 2 0 5 e195inhibitor-1 (PAI-1), factor VII, XII and ﬁbrinogen, reduced tissue
plasminogen activator (tPA) levels, platelet hyper-reactivity.
4.7. Diabetic cardiomyopathy
Diabetic cardiomyopathy is a clinical condition diagnosed
when ventricular dysfunction occurs in the absence of
coronary atherosclerosis and hypertension.
4.8. The metabolic syndrome (MetS)
MetS represents the combination of multiple risk factors.
Patients with MetS have a 2-fold increase of CVD risk and a 5-
fold increase in development of T2DM.
4.9. Endothelial progenitor cells and vascular repair
Impaired function and reduced endothelial progenitor cells are
features of T1DM and T2DM.
4.10. Conclusions
Oxidative stress plays a major role in the development of
micro- and macrovascular complications. Accumulation of
free radicals in the vasculature of patients with DM is
responsible for the activation of detrimental biochemicalpathways, leading to vascular inﬂammation and reactive
oxygen species generation.
5. Cardiovascular risk assessment in patients
with dysglycaemia
5.1. Risk scores developed for people without diabetes
The European Systematic Coronary Risk Evaluation (SCORE)
for fatal CVD was not developed for application in patients
with DM. The 2012 Joint European Society guidelines on CVD
prevention recommended that patients with DM, and at least
one other CV risk factor or target organ damage, should be
considered to be at very high risk and all other patients with DM
to be at high risk. There are other scoring systems in Europe.
5.2. Evaluation of cardiovascular risk in people with pre-
diabetes
High 2hPG, but not FPG, predicted all-cause mortality, CVD and
coronary artery disease (CAD).
5.3. Risk engines developed for people with diabetes
Many risk scores were developed. There was little evidence to
suggest that using risk scores speciﬁc to DM provides a more
accurate estimate of CVD risk. Risk scores for the evaluation of
DM have good results in the populations in which they were
developed, but validation is needed in other populations.
5.4. Risk assessment based on biomarkers and imaging
Albuminuria and elevated circulating NT-proBNP are strong
predictors of excess overall and CV mortality. Cardiovascular
target organ damage: low ankle-brachial index, increased
carotid intima-media thickness, artery stiffness or coronary
artery calcium score, cardiac autonomic neuropathy and silent
cardial ischaemia may account for a part of the cardiovascular
residual risk that remains, even after control of conventional
risk factors. The detection of these biomarkers and disorders
contributes to a more accurate risk estimate and should lead to
a more intensive control of modiﬁable risk factors. However
the cost-effectiveness of this strategy needs to be evaluated.
5.5. Gaps in knowledge
*How to prevent or delay T1DM. *Biomarkers and diagnostic
strategies useful for the early detection of CAD in asymptom-
atic patients. *Prediction of CV risk in people with pre-diabetes
(Table 7).
6. Prevention of cardiovascular disease in
patients with diabetes
6.1. Lifestyle
Healthy eating, regular physical activity and cessation of
smoking are ﬁrst measures for the prevention and/or
Table 7 – Recommendations for cardiovascular risk
assessment in diabetes.
Cardiovasc ular  ris k assessment in diabetes
Recommend aons Class   
a
Level  b Ref.  c
It should be consider ed to classi fy  paents with DM as  at 
very hig h or hig h ris k for CV D depend ing on the pres ence of 
concomi tant ris k fac tor and  targ et organ dam age
IIa C -
It is  not recomm ended to assess th e ris k for CV D in paents 
with DM based on ris k scores developed for the gener al 
popula on.
III C -
It is  ind icated to es mate the uri nary  albumi n excreon 
rate when perform ing ri sk stra ﬁcaon in paents with DM
I B 11 3
Screening for sil ent my ocar dial  is chaemia  may be 
consi der ed in se lec ted high ris k paents with DM
IIb C -
CVD = cardiovascular disease; DM = diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 9 0 – e 2 0 5e196management of T2DM, with targets of weight loss and
reduction of CV risk. An individualized approach to T2DM is
also recommended. Smoking increases the risk of T2DM, CVD
and premature death, and should be avoided. For detailed
instruction on smoking cessation principles, see Table 8. For
recommendations on life style modiﬁcations in diabetes, see
Table 9.
Gaps in knowledge: *Lifestyles that inﬂuence the risk of CVD
among people with DM are constantly changing and need to be
followed. *The CVD risk, caused by the increasing prevalenceTable 9 – Recommendations on life style modifications in
diabetes.
Life style modiﬁca ons in diabetes
Recommend aons Class   
a
Leve l
b
Ref.
c
Smoking cessa on guided by  structured advi ce is 
recomm ended in all  sub jec ts with DM and  IGT
I A 14 8
It is  recommend ed that in the prevenon of T2DM and control 
of DM total  fat intake should be < 35%, sa turated fat <10%, 
and monoun saturated fay acids >10%  of total  energy.
I A 57,1 29, 13
2,134
It is  recommend ed that die tar y ﬁbre  intake should be >40 
g/day (o r 20g/1000 Kcal /day ) in the preven on of T2DM  and 
control of DM
I A 57,1 29, 13
2,134
Any  diet with reduced energy intake can be recommen ded in 
lowering ex cessive  body weight  in DM.
I B 129, 132
Vitam in or micro nutrien t supple mentaon to reduce the ris k 
of T2DM  or CV D in DM is not recommend ed
III B 129, 135
Modera te to vi gorous physical  akvi ty  of ≥150 min/week is 
recomm ended for the preve non and control of T2DM  and 
preve non of CVD in DM
I A 141, 142
Aerobic exercise and  res istance tra ining are  rec ommen ded in 
the prevenon of T2DM and control of DM, but bes t when 
combined.
I A 14 4
CVD = cardiovascular disease, DM = diabetes mellitus, T2DM = type
2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).
Table 8 – The strategic 'five As' for smoking cessation.
A-ASK: Sy stemacally  inquire  about smoking status at every 
opp ortun ity.
A-ADVIS E: Un equ ivocally  urg e all  smokers t o quit.
A-ASSES S: Determi ne the pers on´s degr ee of addicion and 
readiness to quit.
A-ASSIST: Agree on a sm oking ces saon  strategy, includ ing se ng 
a quit date,  behavi oura l counsell ing,  and  
pharmacologi cal  supp ort.
A-ARR ANGE: Ar range a schedu le for foll ow-up .of T2DM in young people due to unhealthy lifestyles. *The
remission in T2DM seen after bariatric surgery and CVD risk.
6.2. Glucose control
Microvascular complications of DM are reduced by tight
glycaemic control (42–53 mmol/mol), which also exerts a
favourable inﬂuence on CVD. A meta-analysis of CV outcomes
suggested that an HbA1c reduction of 1% was associated with a
15% relative risk reduction in nonfatal MI but without beneﬁts
on stroke or all-cause mortality.
Patients with a short duration of T2DM and without a
history of CVD, without trend to hypoglycaemia seemed to
beneﬁt from more-intensive glucose-lowering strategies. In
T1DM and T2DM: (i) glycaemic control is important for
reducing long-term macrovascular complications; (ii) a very
long follow-up period is required to demonstrate an effect and
(iii) early glucose control is important (metabolic memory). An
HbA1c target of <53 mmol/mol to reduce microvascular
disease is a generally accepted level. More stringent targets,
e.g. HbA1c 42–48 mmol/mol might be considered in selected
patients. It is important to individualize treatment targets.
The choice of agent, the conditions of their use and the role
of combination therapy have been extensively reviewed in the
joint ADA/EASD guidelines (Table 10).
Gaps in knowledge: *Long-term CVD outcomes for most
glucose-lowering treatments.
*The consequences of polypharmacy for quality of life and
the most appropriate choice of treatment in DM-patients with
comorbidities, particularly in the elderly. *The level of
glycaemia (FPG, 2hPG, HbA1c) at which CV beneﬁts can be
seen in T2DM (Table 11).
6.3. Blood pressure
The prevalence of hypertension is higher in patients with T1DM
than in the general population (up to 49%) and more than 60% of
patients diagnosed with T2DM. This is related to: (i) hyper-
insulinaemia linked to increased renal reabsorption of sodium;
(ii) increased sympathetic tone and (iii) increased renin–
angiotensin–aldosterone system activity. Obesity, ageing and
the appearance of renal disease further increase the prevalence
of hypertension. Hypertension causes a 4-fold increase in
cardiovascular risk in people with DM. Present evidence makes
it reasonable to reduce blood pressure (BP) in patients with DM
to <140/85 mmHg; further reduction might be associated with
an increased risk of serious adverse events, especially in
patients of advanced age and with longer duration of T2DM.
Thus the risks and beneﬁts of more intensive BP management
need to be carefully considered on an individual basis, e.g. in
patients with nephropathy with overt proteinuria an even lower
BP (SBP <130 mm Hg) may be considered.
To achieve BP goal, a combination of BP-lowering drugs is
needed in most patients. All available BP-lowering drugs can
be used, but evidence strongly supports the inclusion of an
inhibitor of the RAAS (ACE-I/ARB) in the presence of protein-
uria. It should be borne in mind that many DM patients do not
reach the recommended BP target.
Gaps in knowledge: *The consequences of blood pressure-
lowering multi-drug combinations in the elderly. *The evidence
Table 10 – Pharmacological treatment options for T2DM.
Drug class Effect Weight
change
Hypoglycaemia
(monotherapy)
Comments
Metformin Insulin sensitizer Neutral/
loss
No Gastrointestinal side-effects, lactic acidosis, B12 deﬁciency.
Contraindications, low eGFR, hypoxia, dehydration
Sulphonylurea Insulin provider Increase Yes Allergy
Risk for hypoglycaemia and weight gain
Meglitinides Insulin provider Increase Yes Frequent dosing
Risk for hypoglycaemia
Alfa-glucosidase
inhibitor
Glucose absorption
inhibitor
Neutral No Gastrointestinal side-effects
Frequent dosing
Pioglitazone Insulin sensitizer Increase No Heart failure, oedema, fractures, urinary bladder cancer
GLP-I agonist Insulin provider Decrease No Gastrointestinal side-effects
Pancreatitis injectable
DPP-4 inhibitor Insulin provider Neutral No Pancreatitis
Insulin Insulin provider Increase Yes Injectable
Risk for hypoglycaemia and weight gain
SGLT2 inhibitors Blocks renal glucose absorption
in the proximal tubuli
Decrease No Urinary tract infections
eGFR = estimated glomerular ﬁltration rate; GLP-1 = glucagon- like peptide-1; DPP = Diabetes Prevention Program; SGLT2 = sodium glucose co-
transporter 2.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 9 0 – e 2 0 5 e197base for efﬁcacy or harm for microvascular complications for
both individual blood pressure-lowering drugs alone or in
combination. *The role of arterial stiffness in predicting CV risk
in patients with DM, over and above the role of conventional risk
factors. *Optimal blood pressure targets. *Metabolic side-effects
of beta-blockers or diuretics clinically (Table 12).
6.4. Dyslipidaemia
In individuals with T1DM and good glycaemic control, the
pattern of lipid abnormalities contrasts with that of T2DM:
serum TG is normal and HDL-chol is within the upper normal
range or slightly elevated. A cluster of lipid and apoprotein
abnormalities accompanies T2DM, affecting all lipoprotein
classes (Table 6).Table 11 – Recommendations for glycaemic control in
diabetes.
Glyca emic control in  diabetes
Recommend aons Class   
a
Level  
b
Ref.  c
It is  recommend ed that glucose  lo wer ing in instuted in an 
indivi duali zed ma nner  taking du raon of DM, co-morbidies 
and age into ac count.
I C -
It is  recommend ed to apply ght glucose  control, targ eng a 
near-norm al HbA1c <53 mm ol/mol to decrease  microvascul ar 
compli caons in T1DM and  T2DM .
I A 15 1-
153, 155
159
A HbA1c targ et of  ≤53 mmol/mol should be consider ed for the 
preve non of CVD in T1 and T2D M.
IIa C -
Basal bolus insuli n regi men, combined with frequ ent gl ucose 
monitori ng, is  recommend ed for  opmi zing gl ucose  control in 
T1DM.
I A 151, 154
Meorm in should be consi der ed as ﬁrst-line therapy i n subjec ts 
with T2DM foll owing eval uaon of renal fun con.
IIa B 15 3
CVD = cardiovascular disease; DM = diabetes mellitus; HbA1c = gly-
cated haemoglobin A1c; T1DM = type 1 diabetes mellitus;
T2DM = type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).Comprehensive and consistent data exist on the mecha-
nism of action and efﬁcacy of statins in the primary and
secondary prevention of CVD events in T2DM. A 9% reduction
in all-cause mortality and a 21% reduction in the incidence of
major vascular outcomes per mmol/l of LDL-cholesterol
lowering (p < 0.0001) was reported. High dose statin therapy
was associated with risk of new-onset T2DM (OR 1.09; 1.0–1.2),
which increased with age. The small risk of developing DM is
clearly outweighed by the reduction of cardiovascular events.
T2DM patients at the LDL-C target remain at high CV risk,
and this residual risk is linked to many factors including
atherogenic dyslipidemia (Table 6). It has been suggested that
targeting elevated TG (>2.2 mmol/l) and/or low HDL-C
(<1.0 mmol/l) may provide further beneﬁts. Meta-analysesTable 12 – Recommendations for blood pressure control in
diabetes.
Blood pressure control in diabetes
Recommend aons Class   
a
Level  b Ref.  c
Blo od press ure control is recomm end ed in paents with 
DM and hyperte nsi on to lower  the ris k of cardio vas cular 
events.
I A 18 9-191 ,
193-19 5
It is  recommend ed that a paent with hypertension and 
DM is treated in an indiv idual ized ma nner , tar geng a 
blo od pressure of < 140/ 85 mmHg.
I A 19 1-
193, 195
It is  recommend ed that a combinaon of blo od press ure 
lowering ag ents is  used to ac hiev e blood pressure control.
I A 19 2-
195,205 -
207
A RAAS  blocker  (ACE -I or AR B) is  recomm ended in the 
treatment  of hyp ertensio n in DM, parcular ly  in the 
prese nce of proteinuria  or microa lbu minuria.
I A 200, 205 -
207
Simultaneous admi nistraon  of two RAA S blockers  should 
be avoided in paents with DM
III B 209, 210
ACE-I = angiotensin converting enzyme-inhibitors; ARB = angio-
tensin receptor blockers; DM = diabetes mellitus; RAAS = renin
angiotensin aldosterone system.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).
Table 15 – Recommendations for multifactorial risk
management in diabetes.
Mulfactorial ri sk ma nageme nt in  diabetes
Recommend aons Class   
a
Level  
b
Ref.  
c
Risk stra ﬁcaon should be consi dered as part of the eval uaon of 
paents with DM and IGT.
IIa C -
Cardiovasc ular  ris k assessme nt is  recommended in peop le with DM 
and IGT as  a basis  for mulfac torial  manage ment.
I B 156, 213
Treatment targe ts, as  li sted in Table  10, should be consi dered in 
paents with DM and IGT with CV D.
IIa B 156, 213
CVD = cardiovascular disease; DM = diabetes mellitus; HbA1c = gly-
cated haemoglobin A1c; IGT = impaired glucose tolerance;
LDL = low density lipoprotein; T2DM = type 2 diabetes mellitus.
cReference(s) supporting levels of evidence (see original paper).
Table 13 – Recommendations on management of dysli-
pidaemia in diabetes.
Dyslipidaem ia in diabetes
Recommend aons Class   
a
Level 
b
Ref.  
c
Stan ther apy is recommended in paents with T1DM and 
T2DM at very  high-risk (i.e. if combined with docume nted CVD, 
severe CKD or with one or more CV  risk fac tors and /or target 
organ dam age) with an LDL-C  targe t of <1.8 . mm ol/L (<70 
mg/dL) or at le ast a ≥50% LDL-C redu con if this target g oal 
cannot be reached.
I A 227, 234,
238
Stan ther apy is recommended in paents with T2DM at high 
risk (without any other  CV risk fac tor and free of targe t orga n 
damage)  with an LDL-C  target of <2.5  mmol/L (<100 mg /dL).
I A 227, 234
Stans may  be consi dered in T1DM paents at high ris k for  CV
events irrespec ve  of the basa l LDL-C concentraon.
IIb C -
It may  be consi dered to have  a seco ndary go al of non-HDL-C 
<2.6  mm ol/dL (<100 mg /dL) in paents with DM at very  hig h 
risk and of <3.3  mm ol/L (<130 mg /dL) in paents at high ris k.
IIb C -
Intensiﬁcaon of stan therap y should be consi der ed before 
the introducon of combinaon thera py  with the addion  of 
ezemi be.
IIa C -
The use  of drugs th at increase  HDL-C to prevent  CVD in T2D M 
is not recommend ed.
III A 251, 252,
256
CV = cardiovascular; CVD = cardiovascular disease; CKD = chronic
kidney disease; DM = diabetes mellitus; HDL-C = high density lipo-
protein cholesterol; LDL-C = low-density lipoprotein cholesterol;
T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).
Table 16 – Summary of treatment targets for managing
patients with diabetes mellitus or impaired glucose
tolerance and coronary artery disease.
Blood pressure (mmHg) <140/85
In case of nephropathy <130
Glycaemic control Generally < 53 mmol/mol
HbA1c On an individual basis
48–52 mmol/mol
Lipid proﬁle (mmol/l/mg/dL) Very high risk patients
< 1.8 mmol/L (<70 mg/dL) or
reduced by at least 50%
LDL-cholesterol High risk patients < 2.5 mmol/L
(<100 mg/dL)
Platelet stabilization Patients with CVD and DM
ASA 75–160 mg/day
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 9 0 – e 2 0 5e198have conﬁrmed the clinical beneﬁts of ﬁbrates on major CVD
events but not on cardiovascular mortality.
Gaps in knowledge: *The role of HDL particles in the
regulation of insulin secretion in beta-cells. *Efﬁciency and
safety of drugs increasing or improving HDL-C particles. *The
relative contributions of HDL function and plasma HDL
concentration in the pathogenesis of CVD (Table 13).
6.5. Platelet function
Persistent hyperglycaemia have been identiﬁed as major
determinants of in vivo platelet activation in the early and
late phases of the natural history of T2DM. For recommenda-
tion for antiplatelet therapy, see Table 14.
Gaps in knowledge: *The optimal antithrombotic regimen for
the primary prevention of CVD in DM.Table 14 – Recommendations for antiplatelet therapy in
patients with diabetes.
Anplate let therapy in paents wi th diabetes
Recommend aons Class   
a
Level  
b
Ref.  
c
An pla telet ther apy  with as pir in in DM-paents at low C VD 
risk is  not recommend ed.
III A 27 2-27 4
An pla telet ther apy  for prim ary  preve non may  be 
consi der ed in hig h ris k paents with DM on an indivi dual 
basis.
IIb C -
Aspiri n at a dose  of 75 -160 mg /day is  recommen ded as 
secondary  prevenon in DM.
I A 27 0
A P2Y12 receptor blocker  is  recommended in paents with 
DM and ACS for 1 year and  in those subjected to PCI 
(dura on depending on stent type) . In paents with PCI  for 
ACS prefer ably pra sugrel or cagre lor should be give n.
I A 276, 277,
280, 282,
284
Clopidogrel  is  recommended as  an alter nave  anpla telet 
ther apy  in case  of aspiri n intole rance.
I B 280, 285
ACS = acute coronary syndrome; CVD = cardiovascular disease;
DM = diabetes mellitus; PCI = percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).6.6. Multifactorial approaches
Data from the Euro Heart Survey on Diabetes and the Heart
support a multifactorial approach as a cornerstone of patient
management (Table 15). Treatment targets are summarized in
Table 16.
Gaps in knowledge: Pleiotropic effects of glucose-lowering
therapies on CVD outcomes.Smoking Cessation obligatory
Passive smoking None
Physical activity Moderate to vigorous
 150 min/week
Weight Aim for weight stabilization
in the overweight or obese
DM patients based on calorie
balance, and weight reduction
in subjects with IGT to prevent
development of T2DM
Dietary habits
Fat intake (% of dietary energy)
Total <35%
Saturated <10%
Monounsaturated fatty acids >10%
Dietary ﬁbre intake >40 g/day
(or 20 g/1000 kcal/day)
CVD = cardiovascular disease; DM = diabetes mellitus; HbA1c = gly-
cated haemoglobin A1c; IGT = impaired glucose tolerance;
LDL = low density lipoprotein; T2DM = type 2 diabetes mellitus.
Table 17 – Recommendations for the management of
patients with stable and unstable coronary artery disease
and diabetes.
Manageme nt of paent s with stable and  unstable coronary artery dise ase an d diabetes
Recommend aons Class   a Level  b Ref. C
It is  recommend ed that paents with CVD are 
inves gated for disorders of glucose  metabolism.
I A 294, 295
Beta-blockers  should be consi der ed to reduce mortali ty 
and morbidity in paents with DM and ACS.
IIa B 309, 310
ACE-I  or AR Bs are indicated in paents with DM and  CAD 
to reduce the risk for cardiovasc ular  events.
I A 210, 312,
313
Stan ther apy is ind icated in paents with DM and CA D 
to reduce the risk for cardiovasc ular  events.
I A 22 7
Aspiri n is  indicated in paents with DM and CA D to 
redu ce the risk for cardiovas cular  events.
I A 274, 316
Platelet P2Y12 receptor inh ibion is  recomm end ed in 
paents with DM and ACS in add ion to aspirin.
I A 280, 282,
284, 285,
304, 307
Insulin -bas ed gl ycaemic  control should be consider ed in 
ACS paents with sig niﬁcant  hyp erglyc aemi a (>10 
mmol/L or >180 mg /dL) with the targ et adapted to 
possi ble comorbidies.
IIa C -
Glycaemic control, that may  be ac complished by 
diﬀer ent glucose -lower ing agents,  should be  consi der ed 
in paents with DM and ACS.
IIa B 326, 328,
330
ACE-I = angiotensin converting enzyme inhibitor; ACS = acute
coronary syndrome; ADP = adenosine diphosphate; ARB = angio-
tensin receptor blockers; CAD = coronary artery disease; CVD = car-
diovascular disease; DM = diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).
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coronary artery disease in patients with diabetes
7.1. Optimal medical treatment
DM is associated with a poorer prognosis in patients with acute
and stable CAD. All patients with CAD should have their
glycaemic state evaluated. The appropriate screening method
is an OGTT, which should be performed, but not earlier than 4–
5 days after an acute coronary syndrome (ACS) to minimize
false positive results. In-hospital and long-term mortality after
MI has declined, but the outcome is still poor among patients
with DM. The reasons are not fully explained but a higher
prevalence of complications, in combination with lack of
appropriate evidence-based treatment, contributes.
Beta-blockers are advocated for the whole spectrum of CAD.
However they improve prognosis in post-MI patients with DM,
may have negative metabolic effects (increasing IR, masking
hypoglycaemia, etc.). There are some differences between
non-vasodilating metoprolol, atenolol, and vasodilating car-
vedilol or labetalol; on the other hand b1-blockers with
modulation synthesis of NO (nebivolol) have a better gluco-
metabolic proﬁle. Overall the positive effects of beta-blockade
on prognosis outweigh the negative glucometabolic effects.
Treatment with ACE-I or ARBs should be started during
hospitalization for ACS and continued in patients with left
ventricular dysfunction, hypertension, or chronic kidney
disease, in all patients with ST-elevation MI or stable CAD.
The ONTARGET trial improved, that ACE inhibitor and AT II
receptor blockers are equivalent as regards the cardioprotec-
tion; combination of the two drugs is not recommended.
The beneﬁcial effect of statins in patients with CAD and DM
is ﬁrmly established (see above).
There is no evidence for a prognostic impact of nitrates but
they may be used for symptomatic relief. Calcium channel blockers
are efﬁcacious in relieving ischaemic symptoms. Verapamil and
diltiazem may prevent re-infarction and death, they may be
appropriate for long-term use in patients without heart failure,
as an alternative to beta-blockers. The combination of these
drugs and beta-blockers should be avoided. An alternative is the
use of a dihydropyridine calcium channel blockers (amlodipine,
felodipine or nicardipine). Ivabradine is effective in preventing
angina in patients with DM and stable CAD, in patients with
heart rate >70 bpm esp. with left ventricular dysfunction.
Antiplatelet and antithrombotic drugs are indicated in the
same way as in nondiabetic patients.
Elevated plasma glucose during an ACS associated with a
more serious prognosis in DM. Glucose-insulin-potassium
infusion (GIK), regardless of the presence of DM or PG,
improves use of glucose for energy production, endothelial
function and ﬁbrinolysis. Randomized controlled trials failed
to show mortality or morbidity beneﬁts.
Diabetics with ACS will beneﬁt from glycaemic control if
hyperglycaemia is signiﬁcant (>10 mmol/l). Insulin infusion is
the most efﬁcient way to achieve rapid glucose control with less
stringent targets in those with severe co-morbidities. There is a
J- or U-shaped relationship between glucose and prognosis.
Gaps in knowledge: *The role and optimum level of glycaemic
control in the outcome in patients with ACS. *Final infarct sizereduction by means of very early GIK administration after MI
symptoms (Table 17).
7.2. Revascularization
A quarter of myocardial revascularization procedures are per-
formed in patients with DM. Revascularization in these patients
is challenged by a more diffuse atherosclerotic involvement of
epicardial vessels, a higher propensity to develop re-stenosis
after PCI (percutaneous coronary intervention) and saphenous
graft occlusion after coronary artery bypass graft surgery (CABG)
and unremitting atherosclerotic progression causing new
stenosis.
No interaction between the effect of myocardial revasculari-
zation and the presence of DM has been documented in trials on
non-ST-elevation ACS management. An early invasive strategy
improved outcomes in the overall population with a greater
beneﬁt in patients with DM. In STEMI patients, a pooled analysis
of individual patient comparing primary PCI with ﬁbrinolysis
showed that patients with DM treated with reperfusion had an
increased mortality compared with those without DM.
CABG is superior and cost-effective strategy compared with
PCI for patients with DM and advanced CAD. There was no
signiﬁcant interaction based on SYNTAX (SYNergy between
PCI with TAXus and cardiac surgery) score, since the absolute
difference in the primary end points between PCI and CABG
were similar in patients with low, intermediate and high
SYNTAX scores. It can be concluded that a discussion with the
patient, explaining the mortality beneﬁt with CABG surgery,
and an individualized risk assessment should be mandatory
before the type of intervention is decided.
The second-generation everolimus-eluting stents were not
superior in terms of target lesion failure after one year of
Table 18 – Recommendations for coronary revasculariza-
tion of patients with diabetes.
Coronary revasc ularizaon of p aents with diabetes
Recommend aons Class   
a
Level  b Ref.  c
Opmal  me dical treatment should be consi dered as 
prefer red treatment in paent with stable CA D and  DM 
unless ther e are lar ge areas of is chaemi a or sig niﬁcant  le	 
main or proximal LAD le sio ns.
IIa B 33 9
CABG is  recomm ended in paents with DM and mulvesse l 
or complex  (SYNTAX  Score >22) CA D to improve survi val 
free from ma jor car diovascular  events.
I A 337, 339,34
6,350,355,3
74
PCI for symptom control may  be  consi dered as  an 
alternave to CA BG in paents with DM and less  complex 
mulvesse l CA D (SYNTAX  score ≤22)  in need of 
revas culari zaon.
IIb B 347, 349,
350
Primary  PCI is recommen ded over  ﬁbri nolysis  in DM 
paents presenng with STEMI  if performed within 
recomm ended me limits.
I B 34 3
In DM paents subjec ted to PCI, DES rather than BMS ar e 
recomm ended to redu ce risk of targ et vesse l 
revas culari zaon.
I A 351, 352
Renal  fun con should be car efully monitored a	er 
coronary  angiogramy/ PCI in all  paents on meormi n.
I C -
If renal  fun con deteriorates  in paents on meormi n 
undergoing coronary  angiography / PCI it is recomme nded 
to withh old treatment for 48 h or unl renal  funcon has 
returned to its inial le vel.
I C -
BMS = bare-metal stent; CABG = coronary artery bypass grafting;
CAD = coronary artery disease; DES = drug-eluting stent; DM = dia-
betes mellitus; LAD = left anterior descending coronary artery;
PCI = percutaneous coronary intervention; STEMI = ST-elevation
myocardial infarction.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 9 0 – e 2 0 5e200follow-up in a head-to-head comparison with paclitaxel-
eluting stents, while zotarolimus-eluting stents were inferior
to sirolimus-eluting stents in patients with DM. Antithrom-
botic treatment in DM patients undergoing coronary revascu-
larization for stable angina or ACS is no different from those
without DM.
There is no randomized evidence regarding the use of one
vs. two internal thoracic artery (ITA) conduits in DM. A single-
centre non-randomized study comparing CABG with bilateral
ITA and PCI in DM reported improved outcomes (freedom from
angina, re-intervention, or composite major adverse cardiac
events) in the surgical group, but no difference in six-year
survival.
More than 50% of patients with moderate-to-poor blood
glucose control after cardiac surgery may not have been
diagnosed as having DM during pre-operative assessment.
This may lead to inadequate peri-operative glycaemic control,
which is a predictor of in-hospital mortality and morbidity,
although hypoglycaemic medications may inﬂuence the
safety of coronary angiography, as well as early and late
outcomes of revascularization with PCI or CABG (Table 18).
Gaps in knowledge: *The optimal policy on metformin
treatment in patients undergoing PCI. *The role and optimum
level of glycaemic control in the outcome during and after
myocardial revascularization.
8. Heart failure and diabetes
Patients with T2DM were associated with signiﬁcantly
increased risk of developing heart failure (HF). Insulin
resistance and dysglycaemia have unfavourable effects onthe myocardium and leads to the diabetic cardiomyopathy.
Myocardial dysfunction may progress in a time dependent
fashion after the onset of diastolic dysfunction, which can
worsen during physical exercise, leading to systolic dysfunc-
tion and the classical features of HF.
8.1. Prevalence and incidence of HF in T2DM and T2DM in
HF
The prevalence of HF in a general population is 1–4% and 0.3–
0.5% of the patients have both HF and T2DM. There are about
12–30% patients with T2DM in patients with HF. Independent
risk factors for the development of HF in T2DM, including high
HbA1c, increased BMI, advancing age, associated CAD,
retinopathy, nephropathy and insulin use, end-stage renal
disease, proteinuria and albuminuria, and duration of T2DM,
were associated with HF and its progression.
8.2. DM and HF morbidity and mortality
T2DM represents an independent predictor of mortality in all
HF patients, mostly in ischaemic aetiology; the combination of
T2DM and HF resulted in a 12-fold higher annual mortality
than among T2DM without HF.
8.3. Pharmacological managements of HF in T2DM
Drug treatment of HF in patients with T2DM is based on the
three neurohormonal antagonists: ACE-I or ARB, a beta-
blocker and a mineralocorticoid receptor antagonist (MRA)
as in patients without DM. They are usually combined with a
diuretic for relieving congestion; loop diuretics are recom-
mended, rather than thiazides. Surveillance of kidney function
and potassium is mandatory, considering the increased risk of
nephropathy in patients with DM. Ivabradine is useful in
patients with HF in sinus rhythm and heart rate 70 and has
the same effects as in non-DM (see Table 19).
8.4. Non-pharmacological therapies
Cardiac resynchronization therapy is a guideline-recom-
mended HF treatment in speciﬁc groups of patients with or
without DM. There is no additional beneﬁt from implantace
cardioverter deﬁbrillators in a subgroup of patients with T2DM
and HF, compared with patients free from this disease. Cardiac
transplantation is an accepted treatment for end-stage HF. The
presence of DM is not a contra-indication, but the stringent
selection criteria have to be acknowledged. DM was an
independent risk factor for decreased 10-year survival in a
large registry study of patients with transplanted heart.
8.5. Glucose-lowering treatment in patients with HF
The use of metformin is indicated because it is in association
with lower mortality rates, lower rates of all-cause hospital
admission and fewer adverse events. Discrepancies were seen
between sulphonylureas and HF mortality (only observational
data). The PPAR gamma-activating thiazolidinediones induce
sodium retention and plasma volume expansion and therefore
are not recommended in patients with HF. There is a lack of
Table 19 – Recommendations for management of heart
failure in diabetes.
Manageme nt of heart fail ure in diabetes
Recommend aons Cla ss  
a
Level  
b
Ref. 
c
ACE-I is recommended in addion to beta-blockers,  in 
paents with systoli c hear t fail ure and  T2D M to reduce 
mortal ity and  hospital izaon.
I A 391, 394 -
396
In paents with systolic heart fai lure and T2D M, who hav e a 
cle ar ACE-I  intoler ance due to side eﬀec ts,  an ARB may  be 
use d as  an al ter nave  to an ACE-I.
I A 39 7-39 9
A beta-blocker  is  recomme nded in add ion to an ACE-I (or 
an AR B if an ACE-I is not tole rated) in all  paents with 
systoli c heart fail ure and T2DM  to redu ce mortali ty and 
hospitali zaon.
I A 391, 401 -
403, 405,406
An MRA is  recommended for al l paents with persis ng 
sympt oms  (NYHA class  II -IV)  and an LVEF ≤35%  desp ite 
treatment with an ACE-I  (or an AR B if an ACE-I is not 
tole rated) and a beta-blocker,  to reduce the risk of heart 
fail ure hospitali zaon and premature death.
I A 41 1-41 3
Addion  of iva bradine to an ACE-I, beta-blocker  and  MRA 
may be consi dered in paents in si nus rhyt hm with T2D M 
with heart fai lure and LVEF  <40%, w ho have  pers isng 
sympt oms  (NYHA Class II -IV)  and a heart rate >70  b.p.m. 
des pite opmal  tole rated dose  of beta-blocker  in addion to 
ACE (or AR B) and MRA.
IIb B 414, 428
Thia zoli dinediones should not be used in paents with heart 
fail ure and T2DM  since water  retenon may  worse n or 
provo ke heart fail ure.
III B 175, 425,426
ACE-I = angiotensin concerting inhibitor; ARB = angiotensin recep-
tor blocker; LVEF = left ventricular ejection fraction; MRA = miner-
alocorticoid receptor antagonist; NYHA = New York Heart
Association; T2DM = type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).
Table 20 – Recommendations for the management of
arrhythmias in patients with diabetes mellitus.
Manageme nt of arrhythm ias in paents with diabetes melli tus
recomm endaons Cla ss  a Level   b Re f.   c
Screening for AF  should be consi dered since it is  common  in 
paents with DM and increases  morbidity  and  mortali ty.
IIa C -
Oral ancoag ulaon  with VKA s or a NOA C (e.g. dabiga tran, 
rivar oxaban or apixaban) is  recommended in DM paents 
with AF  (par oxysmal  and persi stent) if not contraind icated.
I A 439, 440,4
42,4 43, 44
5-447
Assessment of the ris k of ble eding (i.e. HAS-BLE D score) 
should be consider ed when prescri bing anthromboc 
ther apy  in paents with AF  and DM.
IIa C -
Screening for ris k factors for sudden car diac  death should 
be consi dered in paents with DM.
IIa C -
Impla ntable car dioverter deﬁbrill ators ar e recomme nded  
for paents with DM and is chaemic cardio myo pathy  with 
LVEF  <35%  and those resuscitated from ve ntricular 
ﬁbrillaon or sustai ned ventri cular  tac hycar dia.
I A 45 9
Beta-blockers  ar e recomme nded for DM paents with 
heart fai lure and a	er acute MI to prevent sudden car diac 
death.
I A 391, 401 -
403, 405,
406, 449,
450
AF = atrial ﬁbrillation, DM = diabetes mellitus, EF = ejection frac-
tion, LV = left ventricular, NOAC = new oral anticoagulants, VKA = -
vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 9 0 – e 2 0 5 e201information on the impact of GLP-1 analogues or DPP-4
inhibitors in patients with HF. Regarding the use of insulin, a
retrospective cohort study of patients with DM and a primary
diagnosis of HF did not reveal any association between the use
of insulin and mortality.
Gaps in knowledge: *The impact of glucose-lowering drugs
including metformin, GLP-1 analogues and DPP-IV inhibitors
on the prevention of HF.
9. Arrhythmias: atrial ﬁbrillation and sudden
cardiac death
9.1. Diabetes and atrial ﬁbrillation
Atrial ﬁbrillation (AF) is increasing during the last 2 decades
and DM is frequent in patients with AF (about 13% in
community studies). The independent role of DM as a risk
factor for AF has not been established. When T2DM and AF co-
exist, there is a substantially higher risk of all-cause mortality,
CV death, stroke and HF. Screening for AF can be recom-
mended in selected patient groups with T2DM with any
suspicion of paroxysmal or permanent AF.
Signiﬁcant factors for stroke risk in patients with AF: age,
prior stroke/TIA/thromboembolism, hypertension, DM and
structural heart disease. The new scheme is expressed as an
acronym CHA2DS2-VASc [cardiac failure, hypertension,
age  75 (doubled), DM, stroke (doubled)-vascular disease,
age 65–74 and sex category (female)]. Oral anticoagulation with
vitamin K antagonists (VKAs) or one of the oral direct thrombin
inhibitors (e.g. dabigatran etexilate), or oral factor Xa inhibitors(e.g. rivaroxaban, apixaban, edoxiban, betrixiban) are recom-
mended in patients with AF. VKA should be used in all AF
patients with DM unless contra-indicated; an international
normalized ratio (INR) of 2.0–3.0 is the optimal range for
prevention of stroke and systemic embolism in patients with
DM. A lower target INR (1.8–2.5) has been proposed for the
elderly but this is not based on evidence. Combinations of VKA
with antiplatelet therapy do not offer added beneﬁcial effects
on ischaemic stroke or vascular events and lead to more
bleeding events, and such combinations should be avoided.
Aspirin alone is not recommended for the prevention of
thromboembolic disease in patients with DM and AF but, in
patients unable or unwilling to use anticoagulants, the
combination of aspirin and clopidogrel should be considered
(Table 20).
9.2. Sudden cardiac death
DM was associated with an increased risk of sudden death
(almost 4-fold) greater in women than men. There are some
risk factors for sudden death in DM (microvascular disease,
autonomic neuropathy, nephropathy, hypoglycaemia, etc.).
Gaps in knowledge: *The long-term impact of glycaemic
control on the QTc interval. *The role of hypoglycaemia and
other predictors in sudden cardiac death.
10. Peripheral- and cerebrovascular disease
10.1. Peripheral artery disease (PAD)
The deﬁnition of PAD used by the current ESC Guidelines
includes atherosclerotic lesions in the extracranial carotid and
vertebral, upper and lower extremity, mesenteric and renal
arteries. Although abdominal aortic aneurysm is frequent in
patients with DM, it is not included in the current PAD
deﬁnition. Medical history and physical examination are the
Fig. 5 – Algorithm for treatment of intermittent claudication.
CV = cardiovascular.
Table 22 – Physical examination relevant to peripheral
artery disease.
– Measurement of blood pressure in both arms and notation
of asymmetry between the arms
– Auscultation and palpation of the carotid and cervical areas
– Palpation of the pulses at the upper extremities and if
necessary, performance of Allen's test. The hands must be
carefully inspected
– Abdominal palpation and auscultation at different levels
including the ﬂanks and the iliac regions
– Auscultation of the femoral arteries
– Palpation of the femoral, popliteal, dorsalis pedis, and posterior
tibial arteries
– Inspection of the feet for colour, temperature, integrity of the
skin
– Recording of the presence of ulcerations
– Additional ﬁndings suggestive of LEAD, including calf hair loss
and skin changes, should be noted
– ABI, calculated by dividing the systolic blood pressure at the
tibial or dorsalis pedal level with the brachial pressure. An index
of <0.9 is suggestive of LEAD
ABI = ankle-brachial index, LEAD = lower extremity artery disease.
Table 21 – History relevant to peripheral artery disease.
– Family history of CVD
– Symptoms suggesting angina
– Any walking impairment, e.g. fatigue, aching, cramping, or pain
with localization to buttock, thigh, calf, or foot, particularly
when symptoms are quickly relieved at rest
– Any pain at rest localized to the lower legs or feet and its
association with the upright or recumbent positions
– Any poorly healing wounds of the extremities
– Exertional pain in the upper extremities particularly if associated
with dizziness or vertigo
– Any transistory neurological symptom
– History of abrupt onset hypertension, resistant hypertension
(which may result from renal artery stenosis) or renal failure
– Unusual or post-prandial abdominal pain particularly if
related to eating and associated with weight loss
– Erectile dysfunction
CVD = cardiovascular disease.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 9 0 – e 2 0 5e202cornerstones of diagnostic workup (Tables 21 and 22) although
many patients remain asymptomatic.
10.2. Lower extremity artery diseases (LEAD)
Diabetes is a risk factor particularly for LEAD, for which it
increases risk 2- to 4-fold, and for carotid artery disease. All
patients with PAD should change their life-style and receive
adequate lipid-lowering, antihypertensive and antiplatelet
treatment, with optimal glycaemic control. Beta-blockers are
not contra-indicated in patients with LEAD and DM. An
algorithm for the treatment of intermittent claudication isshown in Fig. 5. Early diagnosis of LEAD in patients with DM is
important for the prediction of the overall CV risk.
Critical limb ischaemia (CLI) is deﬁned by the presence of
ischaemic pain at rest and ischaemic lesions or gangrene
attributable to arterial occlusive disease that is chronic and
distinguishable from acute limb ischaemia. An algorithm for
the management of CLI is provided in Fig. 6.
The diabetic foot is a speciﬁc clinical entity that may involve
neuropathy, trauma, arterial disease, infection and inﬂamma-
tion, often in combination. The serious consequences are
ulceration, gangrene and high rates of amputation. Follow-up
should include patient education, smoking cessation, protec-
tive shoes, periodic foot care and reconstructive foot surgery as
needed. The management of risk factors including glycaemic
control and revascularization surveillance is mandatory.
10.3. Carotid artery disease
DM is an independent risk factor for ischaemic stroke with an
incidence 2.5–3.5 times higher than in people without DM.
Carotid bruits are common in patients with carotid artery
Fig. 6 – Algorithm for the management of critical limb ischaemia. CVD = cardiovascular disease.
Table 23 – Recommendations for management of per-
ipheral artery disease in diabetes.
Manageme nt of periph eral arte ry dise ase in  diabetes
Recommend aons Cla ss  
a
Level  
b
Ref.  
c
It is  recommend ed that paents with DM hav e annu al screening to 
detect PAD and me asureme nt of the ABI  to detect LE AD.
I C -
It is  recommend ed that all  paents with PAD and dia betes  who 
smoke ar e advi sed to stop sm oking.
I B 48 3
It is  recommend ed that paents with PAD and DM have LDL-C 
lowered to <1.8  mm ol/L (<70mg/dL) or by  ≥50% when  the tar get 
level cannot be reac hed.
I A 12 5
It is  recommend ed that paents with PAD and DM have thei r 
blo od pressure controll ed to <140/85 mm  Hg.
I C -
An pla telet  ther apy is  recommen ded in all paents with 
sympt omac PAD and DM without contra ind icaons.
I A 27 4
ABI = ankle-brachial index; DM = diabetes mellitus; LDL-C = low-
density lipoprotein cholesterol; LEAD = lower extremity artery
disease; PAD = peripheral artery disease.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 9 0 – e 2 0 5 e203stenosis. The spectrum of symptoms is wide, only those who
have suffered a stroke or TIA within the past six months are
regarded as symptomatic. Urgent imaging of the brain and
supra-aortic vessels is mandatory in patients presenting with
TIA or stroke. Duplex ultrasonography, computed tomography
angiography and magnetic resonance imaging are indicated to
evaluate carotid artery stenosis. Management depends on
symptoms, severity of the lesion, prognosis for 5-year survival
and the outcome of revascularization procedures. A manage-
ment algorithm is shown in Fig. 7.
Gaps in knowledge: *In comparison with aspirin and
clopidogrel, the efﬁcacy of new antiplatelet drugs in patients
with DM and PAD. *There is a need for comparisons of
endovascular and surgical interventions in different subsets of
patients with DM and concomitant carotid or LEAD (Table 23).
11. Microvascular disease in the eyes and
kidneys
Renal impairment, i.e. elevated urinary albumin excretion
and/or impaired glomerular ﬁltration rate (GFR), is itself an
independent predictor of CV outcomes. Retinopathy is the most
frequent microvascular complication in DM; vision-threateningproliferative retinopathy affects 50% of patients with T1DM.
About 29% patients with T2DM develop vision-threatening
macular oedema. The combination of retinopathy and nephrop-
athy predicts excess CV morbidity and mortality.
Fig. 7 – Algorithm for the management of extra cranial carotid artery. BMT = best medical therapy; CTA = computed
tomography angiography; MRA = magnetic resonance angiography; TIA = transient ischaemic attack.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 9 0 – e 2 0 5e20411.1. Pathophysiology of microvascular disease
Chronic hyperglycaemia induces protein glycation and over-
production of reactive oxygen species leading to vascular
damage and responsive activation of tissue speciﬁc growth/
repair systems. The phenotypic characteristics of microvas-
cular damage are progressive vascular occlusion and increased
vascular permeability.
11.2. Treatment and treatment targets
Lifestyle intervention. There are no trials proving that lifestyle
interventions alone have an effect on the prevention of
nephropathy, neuropathy or retinopathy.
Strict glycaemic control prevents both microvascular and CV
outcomes and progression of renal impairment both in T1DM
and T2DM.
Retinopathy: The recommended target for HbA1c in
bothT1DM and T2DM is <53 mmol/mol. Beyond a certain
level of retinal damage, euglycaemia no longer provides a
beneﬁt against progression of retinopathy. The good glycaemic
control brings the long-term beneﬁt for T1DM. In T2DM,
progressing retinopathy beneﬁts from multifactorial treat-
ment.
Blood pressure (BP): Intensiﬁed BP control (using RAAS
blockers) prevents the onset of microalbuminuria in T2DM,
but not in T1DM. Using ACE-I slowed progression of kidney
disease in T1DM and reduced end-stage renal failure. In T2DM,
high doses of ramipril prevented both renal and cardiovascular
events. ARBs reduced progression from microalbuminuria to
proteinuria and prevented renal events but not CV death. The
currently recommended BP target is <140/85 mmHg, in
patients with hypertension and nephropathy with overtproteinuria and even lower SBP (<130 mmHg) may be consid-
ered if tolerated by the patient. BP control has beneﬁcial effects
on the progression of retinopathy. The recommended thresh-
old is <140/85 mmHg.
Lipid-lowering and antiplatelet therapy: Fibrates and PPARa
agonists may reduce kidney function; fenoﬁbrate reduces
albuminuria and slowed eGFR loss. Statin-plus-ezetimibe
provided CV protection in people with reduced kidney
function and DM. There are no clear target levels of lipids
(cholesterol, triglycerides) for the prevention or retardation of
retinopathy. Patients with T2DM require antiplatelet agents for
secondary prevention of CVD. There is no speciﬁc contra-
indication against the use of aspirin or other antiplatelet
agents, as they do not increase the incidence of intravitreal
haemorrhages.
Vision-threatening retinopathy: Severe non-proliferative or
proliferative retinopathy or any level of DM-related macular
oedema should immediately be referred to an experienced
ophthalmologist (Table 24).
Gaps in knowledge: *The balance between the beneﬁt to
microvascular risk associated with tightening of glycaemic
control and the risk of adverse CV outcomes.
12. Patient-centred care
12.1. General aspects
Patient-centred care emphasizes the person, their experi-
ences, priorities and goals in managing various conditions,
and the partnership between providers and patients. When
this approach is used by a multidisciplinary team with skills in
cognitive behavioural strategies, there will be increased
Table 24 – Recommendations for management of micro-
vascular disease in diabetes.
Manageme nt of microv asc ular dise ase  in  diabetes
Recommend aons Class   
a
Level  
b
Ref.  
c
Screening for the presence of renopathy should be 
consi der ed on annual  basis i n paents with T2DM
IIa B 53 0
Mulfac torial ther apy is recomm ended when renopathy is 
progressi ng ra pidly.
I B 15 6
An HbA1c <53 mm ol/mol and a bloo d press ure <140/85 mmHg 
are recommended for primary  prevenon of renopathy 
rela ted to DM.
I A 152, 161,
191, 512 -
514, 524
Lipid loweri ng should be consi der ed to reduce the progressi on 
of renopathy,  the need for la ser  treatment,  and the need for 
vitrectomy.
IIa B 51 3
It is  recommend ed that proli fer ave DM renopathy is 
treated by pan renal  laser  photocoag ulaon.
I A 53 0
Grid lase r photocoag ulaon should be consi dered in clinically 
signiﬁcant mac ular  oedema.
IIa B 53 2
Iintravi treal  an-vas cula r endothelial gr owth factor ther apy 
should be consider ed in paents with vi sion impairmen t and 
cli nically sig niﬁcant mac ular  oedema involvi ng the fovea.
IIa B 531, 532
BP = blood pressure; DM = diabetes mellitus; HbA1c = glycated
haemoglobin A1c; T2DM = type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence (see original paper).
Table 25 – Recommendations for patient-centred care in
diabetes.
Paent-centred ca re in diabetes
Recommend aons Class   
a
Level  
b
Ref.
C
Paent-centred car e is recommend ed to facil itate shar ed 
control and decision-making within the contex t of paent 
pri ories  and go als.
I C -
Paent- centred cognive behavioural  strategies  ar e 
recomm ended to hel p paents ac hieve  lifes tyle changes  and 
prac se  self-ma nag ement.
I B 53 6-
538, 544
Paent-centred cognive  behavioural  strategies  combined 
with sim pliﬁcaon of dosing regi mens should be consi dered 
to improve me dicaon adh erence.
IIa B 53 9-54 1
Muldis ciplinary  teams  and  nurse -led programm es should be 
consi der ed to support lifes tyle change  and self -manage ment.
IIa B 536, 537,
544, 545
aClass of recommendation.
bLevels of evidence.
cReference(s) supporting levels of evidence (see original paper).
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 9 0 – e 2 0 5 e205success in supporting patients in achieving lifestyle changes
and effectively self-managing their conditions. The ongoing
support and booster sessions will be necessary for sustained
change (Table 25).
12.2. Gaps in knowledge
Effects of patient-centred interventions on outcome measures,
including micro- and macrovascular complications.
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